007-004-00-1,nitric acid … %,231-714-2,7697-37-2, Ox. Liq. 2 Skin Corr. 1A , H272 H314 , GHS03 GHS05 Dgr , H272 H314 ,EUH071, Skin Corr. 1A; H314: C ≥ 20 % Skin Corr. 1B; H314: 5 % ≤ C < 20 % Ox. Liq. 2; H272: C ≥ 99 % Ox. Liq. 3; H272: 99 % > C ≥ 65 % ,B, 015-003-00-2,calcium phosphide; tricalcium diphosphide,215-142-0,1305-99-3, Water-react. 1 Acute Tox. 2 Acute Tox. 3 Acute Tox. 1 Eye Dam. 1 Aquatic Acute 1 , H260 H300 H311 H330 H318 H400 , GHS02 GHS06 GHS05 GHS09 Dgr , H260 H300 H311 H330 H318 H400 , EUH029 EUH032 ,M = 100,, 031-001-00-4,gallium arsenide,215-114-8,1303-00-0, Repr. 1B Carc. 1B STOT RE 1 , H360F H350 H372 (respiratory and haematopoietic systems) , GHS08 Dgr , H360F H350 H372 (respiratory and haematopoietic systems) ,,,, 050-008-00-3,tributyltin compounds, with the exception of those specified elsewhere in this annex,—,—, Repr. 1B Acute Tox. 3 Acute Tox. 4* STOT RE 1 Skin Irrit. 2 Eye Irrit. 2 Aquatic Acute 1 Aquatic Chronic 1 , H360FD H301 H312 H372** H315 H319 H400 H410 , GHS08 GHS06 GHS09 Dgr , H360FD H301 H312 H372** H315 H319 H410 ,, * STOT RE 1; H372: C ≥ 1 % STOT RE 2; H373: 0,25 % ≤ C < 1 % Skin Irrit. 2; H315:C ≥ 1 % Eye Irrit. 2; H319:C ≥ 1 % M = 10 , A 1 , 603-102-00-9,1,2-epoxybutane,203-438-2,106-88-7, Flam. Liq. 2 Carc. 2 Acute Tox. 4* Acute Tox. 4* Acute Tox. 4* STOT SE 3 Skin Irrit. 2 Eye Irrit. 2 , H225 H351 H302 H312 H332 H335 H315 H319 , GHS02 GHS08 GHS07 Dgr , H225 H351 H302 H312 H332 H335 H315 H319 ,,,, 603-197-00-7,tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol,403-640-2,107534-96-3, Repr. 2 Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 , H361d*** H302 H400 H410 , GHS08 GHS07 GHS09 Wng , H361d*** H302 H410 ,, M = 1 M = 10 ,, 606-054-00-7,isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α,α,α-trifluoro-2-mesyl-p-tolyl ketone,—,141112-29-0, Repr. 2 Aquatic Acute 1 Aquatic Chronic 1 , H361d*** H400 H410 , GHS08 GHS09 Wng , H361d*** H410 ,, M = 10 M = 100 ,, 607-197-00-8,nonanoic acid,203-931-2,112-05-0, Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 , H315 H319 H412 , GHS07 Wng , H315 H319 H412 ,,,, 613-042-00-5,imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1 H -imidazole,252-615-0,35554-44-0, Carc. 2 Acute Tox. 3 Acute Tox. 4 Eye Dam. 1 Aquatic Chronic 1 , H351 H301 H332 H318 H410 , GHS08 GHS06 GHS05 GHS09 Dgr , H351 H301 H332 H318 H410 ,,M = 10,, 613-057-00-7,dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine,216-474-9,1593-77-7, Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 , H361d H373 (liver) H314 H317 H400 H410 , GHS08 GHS05 GHS07 GHS09 Dgr , H361d H373 (liver) H314 H317 H410 ,EUH071, M = 1 M = 1 ,, 613-133-00-X,etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole,219-991-8,2593-15-9, Carc. 2 Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H351 H302 H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H351 H302 H317 H410 ,, M = 1 M = 1 ,, 613-149-00-7,pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one,405-700-3,96489-71-3, Acute Tox. 3 Acute Tox. 3 Aquatic Acute 1 Aquatic Chronic 1 , H331 H301 H400 H410 , GHS06 GHS09 Dgr , H331 H301 H410 ,, M = 1 000 M = 1 000 ,, 019-003-00-3,potassium (E,E)-hexa-2,4-dienoate,246-376-1,24634-61-5,Eye Irrit. 2,H319, GSH07 Wng ,H319,,,, 604-092-00-9, phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] ,310-154-3 [1], 121158-58-5 [1] 74499-35-7 [2] , Skin Corr. 1C Aquatic Acute 1 Aquatic Chronic 1 , H314 H400 H410 , GHS05 GHS09 Dgr , H314 H410 ,, M = 10 M = 10 ,, 606-148-00-8, carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] , 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] , 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] ,Skin Sens. 1,H317, GHS07 Wng ,H317,,,, 606-149-00-3,tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione,—,335104-84-2, Repr. 2 STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H361d H373 (eyes, kidneys, liver) H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H361d H373 (eyes, kidneys, liver) H317 H410 ,, M = 100 M = 10 ,, 607-707-00-9,fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate,—,71283-80-2, STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H373 (kidneys) H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H373 (kidneys) H317 H410 ,, M = 1 M = 1 ,, 607-708-00-4,octanoic acid,204-677-5,124-07-2, Skin Corr. 1C Aquatic Chronic 3 , H314 H412 , GHS05 Dgr , H314 H412 ,,,, 607-709-00-X,decanoic acid,206-376-4,334-48-5, Skin Irrit. 2 Eye Irrit. 2 Aquatic Chronic 3 , H315 H319 H412 , GHS07 Wng , H315 H319 H412 ,,,, 607-710-00-5,1,2-benzenedicarboxylic acid, dihexyl ester, branched and linear,271-093-5,68515-50-4,Repr. 1B,H360FD, GHS08 Dgr ,H360FD,,,, 607-711-00-0,spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate,—,203313-25-1, Repr. 2 STOT SE 3 Eye Irrit. 2 Skin Sens. 1A Aquatic Acute 1 Aquatic Chronic 1 , H361fd H335 H319 H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H361fd H335 H319 H317 H410 ,, M = 1 M = 1 ,, 607-712-00-6,dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate,250-778-2,31717-87-0, Repr. 2 STOT RE 2 Skin Corr. 1C Skin Sens. 1A Aquatic Chronic 1 , H361d H373 (liver) H314 H317 H410 , GHS08 GHS05 GHS07 GHS09 Dgr , H361d H373 (liver) H314 H317 H410 ,EUH071,M = 1,, 607-713-00-1,fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate,—,134098-61-6, Acute Tox. 3 Acute Tox. 2 Skin Sens. 1B Aquatic Acute 1 Aquatic Chronic 1 , H301 H330 H317 H400 H410 , GHS06 GHS09 Dgr , H301 H330 H317 H410 ,, M = 100 M = 1 000 ,, 607-714-00-7,triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate,—,126535-15-7, Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 , H351 H400 H410 , GHS08 GHS09 Wng , H351 H410 ,, M = 100 M = 10 ,, 607-715-00-2,bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate,442-820-5,149877-41-8, STOT RE 2 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H373 H317 H400 H410 , GHS08 GHS07 GHS09 Wng , H373 H317 H410 ,, M = 1 M = 1 ,, 613-319-00-0,imidazole,206-019-2,288-32-4, Repr. 1B Acute Tox. 4 Skin Corr. 1C , H360D H302 H314 , GHS08 GHS07 GHS05 Dgr , H360D H302 H314 ,,,, 613-320-00-6,lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione,218-499-0,2164-08-1, Carc. 2 Aquatic Acute 1 Aquatic Chronic 1 , H351 H400 H410 , GHS08 GHS09 Wng , H351 H410 ,, M = 10 M = 10 ,, 616-213-00-2,mandipropamid (ISO); 2-(4-chlorophenyl)- N -{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide,—,374726-62-2, Aquatic Acute 1 Aquatic Chronic 1 , H400 H410 , GHS09 Wng ,H410,, M = 1 M = 1 ,, 616-214-00-8,metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide,—,139528-85-1, Carc. 2 STOT RE 2 Aquatic Acute 1 Aquatic Chronic 1 , H351 H373 (eyes, kidneys) H400 H410 , GHS08 GHS09 Wng , H351 H373 (eyes, kidneys) H410 ,, M = 1 000 M = 100 ,, 616-215-00-3,dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide,—,163515-14-8, Acute Tox. 4 Skin Sens. 1 Aquatic Acute 1 Aquatic Chronic 1 , H302 H317 H400 H410 , GHS07 GHS09 Wng , H302 H317 H410 ,, M = 10 M = 10 ,, 616-216-00-9,flonicamid (ISO); N -(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide,—,158062-67-0,Acute Tox. 4,H302, GHS07 Wng ,H302,,,, 616-217-00-4,sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide,—,946578-00-3, Acute Tox. 4 Aquatic Acute 1 Aquatic Chronic 1 , H302 H400 H410 , GHS07 GHS09 Wng , H302 H410 ,, M = 1 M = 1 ,, 007-004-00-1,nitric acid … %,231-714-2,7697-37-2, O; R8 C; R35 , O; C R: 8-35 S: (1/2-)26-28- 36/37/39-45-63 , O; R8: C ≥ 65 % C; R35: C ≥ 20 % C; R34: 5 % ≤ C < 20 % ,B, 015-003-00-2,calcium phosphide; tricalcium diphosphide,215-142-0,1305-99-3, F; R15/29 T+; R26/28 Xn; R21 R32 Xi; R38-41 N; R50 , F; T+; N R: 15/29-21-26/28-32-38-41-50 S:(1/2-)26-28-30-36/37/39-43-45-60-61 ,N; R50: C ≥ 0,25 %,, 031-001-00-4,gallium arsenide,215-114-8,1303-00-0, Repr. Cat. 2; R60 Carc. Cat. 2; R45 T; R48/23 , T R: 45-48/23-60 S: 45-53 ,,E, 050-008-00-3,tributyltin compounds, with the exception of those specified elsewhere in this annex,—,—, Repr. Cat. 2; R60-61 T; R25-48/23/25 Xn; R21 Xi; R36/38 N; R50-53 , T; N R: 21-25-36/38-48/23/25-50/53-60-61 S: 45-53-60-61 , T; R25: C ≥ 2,5 % Xn; R22: 0,25 % ≤ C < 2,5 % Xn: R21: C ≥ 1 % T; R48/23/25: C ≥ 1 % Xn; R48/20/22: 0,25 % ≤ C < 1 % Xi; R36/38: C ≥ 1 % N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % , A 1 , 603-102-00-9,1,2-epoxybutane,203-438-2,106-88-7, F; R11 Carc. Cat. 3; R40 Xn; R20/21/22 Xi; R36/37/38 , F; Xn R: 11-20/21/22-36/37/38-40- S: (2-)9-16-29-36/37-46 ,,, 603-197-00-7,tebuconazole (ISO); 1-(4-chlorophenyl)-4,4-dimethyl-3-(1,2,4-triazol-1-ylmethyl)pentan-3-ol,403-640-2,107534-96-3, Repr. Cat. 3; R63 Xn; R22 N; R50-53 , Xn; N R: 22-50/53-63 S: (2-)22-36/37-60-61 , N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 606-054-00-7,isoxaflutole (ISO); 5-cyclopropyl-1,2-oxazol-4-yl α, α,α-trifluoro-2-mesyl- p -tolyl ketone,—,141112-29-0, Repr. Cat. 3; R63 N; R50-53 , Xn; N R: 50/53-63 S: (2-)36/37-60-61 , N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % ,, 607-197-00-8,nonanoic acid,203-931-2,112-05-0, Xi; R36/38 N; R51-53 , Xi; N R: 36/38-51/53 S: (2-)46-61 ,,, 613-042-00-5,imazalil (ISO); 1-[2-(allyloxy)-2-(2,4-dichlorophenyl)ethyl]-1 H -imidazole,252-615-0,35554-44-0, Carc. Cat. 3; R40 Xn; R20/22 Xi; R41 N; R51-53 , Xn; N R: 20/22-40-41-51/53 S: (2-)26-36/37/39-46-61 ,,, 613-057-00-7,dodemorph (ISO); 4-cyclododecyl-2,6-dimethylmorpholine,216-474-9,1593-77-7, Repr. Cat. 3; R63 C; R34 R43 N; R50-53 , C; N R: 34-43-50/53-63 S: (1/2-)26-28-36/37/39-45-60-61 , C; R34: C ≥ 10 % Xi; R36/37/38: 5 % ≤ C < 10 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 613-133-00-X,etridiazole (ISO); 5-ethoxy-3-trichloromethyl- 1,2,4-thiadiazole,219-991-8,2593-15-9, Carc. Cat. 3; R40 Xn; R22 R43 N; R50-53 , Xn; N R: 22-40-43-50/53 S: (2-)36/37-46-60-61 , N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 613-149-00-7,pyridaben (ISO); 2-tert-butyl-5-(4-tert-butylbenzylthio)-4-chloropyridazin-3(2H)-one,405-700-3,96489-71-3, T; R23/25 N; R50-53 , T; N R: 23/25-50/53 S: (1/2-)36/37-45-60-61 , N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52-53: 0,00025 % ≤ C < 0,0025 % ,, 019-003-00-3,potassium (E,E)-hexa-2,4-dienoate,246-376-1,24634-61-5,Xi; R36, Xi R: 36 S: (2-)25-46 ,,, 604-092-00-9, phenol, dodecyl-, branched [1]; phenol, 2-dodecyl-, branched; phenol, 3-dodecyl-, branched; phenol, 4-dodecyl-, branched; phenol, (tetrapropenyl) derivatives [2] ,310-154-3 [1]-[2], 121158-58-5 [1] 74499-35-7 [2] , C; R34 N; R50-53 , C; N R: 34-50/53 S: (1/2-)26-36/37/39-45-61 , N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % ,, 606-148-00-8, carvone (ISO); 2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [1] d-carvone; (5S)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one; [2] l-carvone; (5R)-2-methyl-5-(prop-1-en-2-yl)cyclohex-2-en-1-one [3] , 202-759-5 [1] 218-827-2 [2] 229-352-5 [3] , 99-49-0 [1] 2244-16-8 [2] 6485-40-1 [3] ,R43, Xi R: 43 S: (2-)24-37 ,,, 606-149-00-3,tembotrione (ISO); 2-{2-chloro-4-(methylsulfonyl)-3-[(2,2,2-trifluoroethoxy)methyl]benzoyl}cyclohexane-1,3-dione,,335104-84-2, Repr. Cat. 3; R63 Xn; R48/22 R43 N; R50-53 , Xn; N R: 43-48/22-50/53-63 S: (2-)36/37-46-60-61 , N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % ,, 607-707-00-9,fenoxaprop-P-ethyl (ISO); ethyl (2R)-2-{4-[(6-chloro-1,3-benzoxazol-2-yl)oxy]phenoxy}propanoate,—,71283-80-2, Xn; R48/22 R43 N; R50-53 , Xn; N R: 43-48/22-50/53 S: (2-)24-37-46-60-61 , N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 607-708-00-4,octanoic acid,204-677-5,124-07-2, C; R34 N; R51-53 , C; N R: 34-51/53 S: (1/2-)26-36/37/39-45-61 ,,, 607-709-00-X,decanoic acid,206-376-4,334-48-5, Xi; R36/38 N; R51-53 , Xi; N R: 36/38-51/53 S: (2-)25-46-61 ,,, 607-710-00-5,1,2-Benzenedicarboxylic acid, dihexyl ester, branched and linear,271-093-5,68515-50-4,Repr. Cat. 2; R60-61, T R: 60-61 S: 53-45 ,,, 607-711-00-0,spirotetramat (ISO); (5s,8s)-3-(2,5-dimethylphenyl)-8-methoxy-2-oxo-1-azaspiro[4,5]dec-3-en-4-yl ethyl carbonate,—,203313-25-1, Repr. Cat. 3; R62-63 Xi; R36/37 R43 N; R50-53 , Xn; N R: 36/37-43-50/53-62-63 S: (2-)36/37-60-61 , Xi; R43: C ≥ 0,1 % N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 607-712-00-6,dodemorph acetate; 4-cyclododecyl-2,6-dimethylmorpholin-4-ium acetate,250-778-2,31717-87-0, Repr. Cat. 3; R63 C; R34 R43 N; R51-53 , C; N R: 34-43-51/53-63 S: (1/2-)26-28-36/37/39-45-61 , C; R34: C ≥ 10 % Xi: R36/37/38: 5 % ≤ C < 10 % ,, 607-713-00-1,fenpyroximate (ISO); tert-butyl 4-[({(E)-[(1,3-dimethyl-5-phenoxy-1H-pyrazol-4-yl)methylene]amino}oxy)methyl]benzoate,—,134098-61-6, T+; R26 Xn; R22 R43 N; R50-53 , T+; N R: 22-26-43-50/53 S: (1/2-)28-36/37-45-60-61-63 , N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % ,, 607-714-00-7,triflusulfuron-methyl; methyl 2-({[4-(dimethylamino)-6-(2,2,2-trifluoroethoxy)-1,3,5-triazin-2-yl]carbamoyl}sulfamoyl)-3-methylbenzoate,—,126535-15-7, Carc. Cat. 3; R40 N; R50-53 , Xn; N R: 40-50/53 S: (2-)36/37-60-61 , N; R50-53: C ≥ 0,25 % N; R51-53: 0,025 % ≤ C < 0,25 % R52-53: 0,0025 % ≤ C < 0,025 % ,, 607-715-00-2,bifenazate (ISO); isopropyl 2-(4-methoxybiphenyl-3-yl)hydrazinecarboxylate,442-820-5,149877-41-8, R43 N; R50-53 , Xi; N R: 43-50/53 S: (2-)24-37-60-61 , N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 613-319-00-0,imidazole,206-019-2,288-32-4, Repr. Cat 2; R61 Xn; R22 C; R34 , T; C R: 22-34-61 S: 53-45 ,,, 613-320-00-6,lenacil (ISO); 3-cyclohexyl-6,7-dihydro-1H-cyclopenta[d]pyrimidine-2,4(3H,5H)-dione,218-499-0,2164-08-1, Carc. Cat. 3; R40 N; R50-53 , Xn; N R: 40-50/53 S: (2-)36/37-60-61 , N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % ,, 616-213-00-2,mandipropamid (ISO); 2-(4-chlorophenyl)- N -{2-[3-methoxy-4-(prop-2-yn-1-yloxy)phenyl]ethyl}-2-(prop-2-yn-1-yloxy)acetamide,—,374726-62-2,N; R50-53, N R: 50/53 S: 60-61 , N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C <25 % R52-53: 0,25 % ≤ C < 2,5 % ,, 616-214-00-8,metosulam (ISO); N-(2,6-dichloro-3-methylphenyl)-5,7-dimethoxy[1,2,4]triazolo[1,5-a]pyrimidine-2-sulfonamide,—,139528-85-1, Carc. Cat. 3; R40 Xn; R48/22 N; R50-53 , Xn; N R: 40-48/22-50/53 S: (2-)36/37-46-60-61 , N; R50-53: C ≥ 0,025 % N; R51-53: 0,0025 % ≤ C < 0,025 % R52/53: 0,00025 % ≤ C < 0,0025 % ,, 616-215-00-3,dimethenamid-P (ISO); 2-chloro-N-(2,4-dimethyl-3-thienyl)-N-[(2S)-1-methoxypropan-2-yl]acetamide,—,163515-14-8, Xn; R22 R43 N; R50-53 , Xn; N R: 22-43-50/53 S: (2-)24-37-60-61 , N; R50-53: C ≥ 2,5 % N; R51-53: 0,25 % ≤ C < 2,5 % R52-53: 0,025 % ≤ C < 0,25 % ,, 616-216-00-9,flonicamid (ISO); N -(cyanomethyl)-4-(trifluoromethyl)pyridine-3-carboxamide,—,158062-67-0,Xn; R22, Xn R: 22 S: (2-)46 ,,, 616-217-00-4,sulfoxaflor (ISO); [methyl(oxo){1-[6-(trifluoromethyl)-3-pyridyl]ethyl}-λ6-sulfanylidene]cyanamide,—,946578-00-3, Xn; R22 N; R50-53 , Xn; N R: 22-50/53 S: (2-)60-61 , N; R50-53: C ≥ 25 % N; R51-53: 2,5 % ≤ C < 25 % R52-53: 0,25 % ≤ C < 2,5 % ,,